A synthetic four-amino-acid peptide modeled on a cow pineal extract, studied in Russia for melatonin output and telomerase in cells.
Also called Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly, Alanyl-glutamyl-aspartyl-glycine
Epitalon is four amino acids long: alanine, glutamic acid, aspartic acid, glycine. Vladimir Khavinson's institute in St. Petersburg designed it around 2000 from the amino acid makeup of Epithalamin, an extract of cow pineal glands that the same group had used in patients since the 1970s and 80s. Most claims you read online about Epitalon actually come from Epithalamin studies, which tested a different product.
The headline finding is from cell culture. In 2003 the group added Epitalon to human fetal fibroblasts and reported that the cells switched on telomerase and lengthened their telomeres. In a 2004 follow-up, treated lung fibroblasts made 10 extra divisions past the point where untreated cells stopped, and were still dividing when the experiment ended. A 2025 study from Brunel University in London, an independent lab, saw the same telomere lengthening in normal human cells, and also saw it in two breast cancer cell lines through a different route called ALT.
Human data on Epitalon itself are thin: a 2002 retinitis pigmentosa report, a 2007 report that Epitalon and the extract raised night melatonin in elderly people, a small sublingual study in women showing more melatonin breakdown product in urine, and lab work on blood cells taken from elderly donors. Nearly all of it comes from one research network, most of it is in Russian-language journals, and none of it measured telomere length, disease, or survival in people taking the peptide.
What it binds to, and what happens inside the body after that, step by step.
The proposed mechanism comes from the Khavinson group: the peptide is small enough to enter cells and the nucleus, where they argue it binds DNA and histone proteins near gene promoters and changes which genes are read. In cultured cells this shows up as telomerase activation, looser packing of old chromatin, and higher output of the melatonin-making enzyme AANAT in rat pineal cells. No receptor has been identified, and the DNA-binding model rests largely on docking simulations and test-tube binding. A 2003 test on whole rat pineal glands kept alive outside the body found no change in melatonin release.
Human results and animal results are kept apart below. A result in rats tells you a mechanism is plausible. It does not tell you what happens in a person.
In humans, Epitalon has only small studies from the group that invented it: a 2002 eye report compared against conventional treatment, a 2007 melatonin report in elderly people, and a 75-person sublingual study measuring a melatonin breakdown product. None describes randomization or blinding. The telomere and lifespan results are from cell culture and mice, and the mouse lifespan effect was limited to the longest-lived animals, with no change in average lifespan. The often-quoted reductions in human mortality come from Epithalamin, the pineal extract, not from Epitalon.
Patients aged 18 to 72 with retinitis pigmentosa (162 per a 2025 review), plus Campbell rats
Authors reported a positive clinical effect in 90 percent of treated patients; the comparison group got conventional drugs, with no placebo, and no randomization or blinding is described.
Read the study75 women with reduced melatonin output, per a 2025 review that reports placebo and control groups; randomization and blinding are not described
Urinary 6-sulfatoxymelatonin, the main melatonin breakdown product, rose 1.7-fold and Clock and Csnk1e gene overactivity in white blood cells fell about 2-fold.
Read the studyTelomerase-negative human fetal fibroblasts in culture
Epitalon switched on the telomerase catalytic subunit, telomerase activity, and telomere lengthening in cells that normally lack telomerase.
Read the studyHuman fetal lung fibroblasts at the end of their division life
Treated cells regained early-passage telomere length and went 10 extra divisions (44 passages versus 34) and were still dividing.
Read the studyNormal human epithelial cells, fibroblasts, and two breast cancer cell lines
Independent UK lab: dose-dependent telomere lengthening in normal cells through hTERT and telomerase, and in cancer cells through the ALT pathway.
Read the study108 female SHR mice, 54 per group, injected 5 days a month for life
No change in mean lifespan or total tumor rate; the longest-lived 10 percent lived 13.3 percent longer, maximum lifespan rose 12.3 percent, and leukemia was 6 times less common.
Read the studyBlood lymphocytes from 11 donors, young and middle-aged
Telomere length changed in 7 of 11 people: up in 5 (18 to 156 percent) and down in 2, tending to move toward the group average.
Read the studyThese are questions the published research has not answered.
No product containing Epitalon is approved as a medicine by the FDA.
Not approved as a drug by FDA, EMA, or any regulator we could verify. The parent extract, Epithalamin, has been used clinically in Russia. Epitalon is not named on the WADA list but falls under S0 (non-approved substances), which bans any pharmacological substance without government approval for human use, in and out of competition. Belgian regulators identified Epitalon in illegal pharmaceutical preparations in 2015.
No human half-life has been published for Epitalon, so we do not draw a clearance curve. Half-lives quoted online for it are usually estimates from animal data.
This table records the doses that trials and approved labels used, with the source for each row. It is a record of research, not a recommendation, and it is open to free members.
Which symptoms are expected and which mean stop and get help: side effects and red flags.
Tap a claim to see what the studies found.
It lengthened telomeres in cultured cells in two separate labs. Nobody has measured telomere length in people taking it under controlled conditions. In blood cells from 11 donors treated in a dish, telomeres got longer in 5 and shorter in 2.
That figure comes from a 12-year study of Epithalamin, the cow pineal extract, not Epitalon. The extract studies came from the same group, were not blinded, and have not been repeated by others.
In SHR mice, average lifespan did not change. Only the longest-lived 10 percent lived longer, by 13.3 percent. There are no human lifespan data.
In a 75-person Russian study, a urine marker of melatonin rose 1.7-fold in women with low output. Sleep itself was not reported as an outcome. In isolated rat pineal glands, a 2003 study found Epitalon did not change melatonin release.
One mouse strain had less leukemia and another had fewer metastases, but total tumor rates did not change in the main lifespan study, and telomerase activation is a known feature of cancer cells. There are no human cancer data.
Short courses come from the Russian clinical tradition with the extracts. No trial has compared cycle lengths or schedules with Epitalon.
These pairings come up often. Almost none have been tested together in a trial, and the evidence note on each says so plainly.
Mirrors the Russian practice of pairing a pineal peptide with Thymalin, the thymus extract.
EvidenceThe combined mortality data (266 elderly people over 6 to 8 years) used Epithalamin and Thymalin extracts, not synthetic Epitalon, in an unblinded study from the developers.
No published stability study. Labs generally keep freeze-dried peptides frozen at about -20 C, dry and away from light.
No published stability data for Epitalon in solution. Short peptides in water degrade faster than the dry powder, and labs typically refrigerate and use solutions promptly.
One email when a trial reads out, a label changes or the FDA acts on a peptide. Free, no selling of peptides, unsubscribe any time.